Additional File 2: of A Large Cohort Study Identifying a Novel Prognosis Prediction Model for Lung Adenocarcinoma Through Machine Learning Strategies

Yin Liu,Di Ge,Jun Gu,Fan Xu,Qinqing Zhu,Lu Chen

DOI: https://doi.org/10.6084/m9.figshare.9776897

2019-01-01

Abstract:Table S1. Clinical information of LUAD patients from TCGA and GEO data repositories (XLSX 269 kb)

What problem does this paper attempt to address?

Additional File 6: of A Large Cohort Study Identifying a Novel Prognosis Prediction Model for Lung Adenocarcinoma Through Machine Learning Strategies

Yin Liu,Di Ge,Jun Gu,Fan Xu,Qinqing Zhu,Lu Chen

DOI: https://doi.org/10.6084/m9.figshare.9776927

2019-01-01

Abstract:Table S5. LASSO coefficient (XLSX 9 kb)
Additional File 1 of Integration of Single-Cell Regulon Atlas and Multi-Omics Data for Prognostic Stratification and Personalized Treatment Prediction in Human Lung Adenocarcinoma

Yi Xiong,Yihao Zhang,Yu Yao,Yueshuo Li,Hongwei Liu,Qian Yang,Yu Chen,Xia Zhang,Xin Chen,Siyi Wanggou,Xuejun Li

DOI: https://doi.org/10.6084/m9.figshare.23751836

2023-01-01

Abstract:Additional file 1: Table S1. Basic information of included datasets. Table S2. Identification of prognostic regulons. Table S3. LPRI of all included datasets.
LUADpp: an Effective Prediction Model on Prognosis of Lung Adenocarcinomas Based on Somatic Mutational Features

Jiaxian Yu,Yueming Hu,Yafei Xu,Jue Wang,Jiajie Kuang,Wei Zhang,Jianlin Shao,Dianjing Guo,Yejun Wang

DOI: https://doi.org/10.1186/s12885-019-5433-7

IF: 4.638

2019-01-01

BMC Cancer

Abstract:Lung adenocarcinoma is the most common type of lung cancers. Whole-genome sequencing studies disclosed the genomic landscape of lung adenocarcinomas. however, it remains unclear if the genetic alternations could guide prognosis prediction. Effective genetic markers and their based prediction models are also at a lack for prognosis evaluation. We obtained the somatic mutation data and clinical data for 371 lung adenocarcinoma cases from The Cancer Genome Atlas. The cases were classified into two prognostic groups (3-year survival), and a comparison was performed between the groups for the somatic mutation frequencies of genes, followed by development of computational models to discrete the different prognosis. Genes were found with higher mutation rates in good (≥ 3-year survival) than in poor (< 3-year survival) prognosis group of lung adenocarcinoma patients. Genes participating in cell-cell adhesion and motility were significantly enriched in the top gene list with mutation rate difference between the good and poor prognosis group. Support Vector Machine models with the gene somatic mutation features could well predict prognosis, and the performance improved as feature size increased. An 85-gene model reached an average cross-validated accuracy of 81% and an Area Under the Curve (AUC) of 0.896 for the Receiver Operating Characteristic (ROC) curves. The model also exhibited good inter-stage prognosis prediction performance, with an average AUC of 0.846 for the ROC curves. The prognosis of lung adenocarcinomas is related with somatic gene mutations. The genetic markers could be used for prognosis prediction and furthermore provide guidance for personal medicine.
A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies

Yin Li,Di Ge,Jie Gu,Fengkai Xu,Qiaoliang Zhu,Chunlai Lu

DOI: https://doi.org/10.1186/s12885-019-6101-7

IF: 4.638

2019-09-05

BMC Cancer

Abstract:<h3 class="Heading">Background</h3><p class="Para">Predicting lung adenocarcinoma (LUAD) risk is crucial in determining further treatment strategies. Molecular biomarkers may improve risk stratification for LUAD.</p><h3 class="Heading">Methods</h3><p class="Para">We analyzed the gene expression profiles of LUAD patients from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). We initially used three distinct algorithms (sigFeature, random forest, and univariate Cox regression) to evaluate each gene's prognostic relevance. Survival related genes were then fitted into the least absolute shrinkage and selection operator (LASSO) model to build a risk prediction model for LUAD. After 100,000 times of calculation and model construction, a 16-gene-based prediction model capable of classifying LUAD patients into high-risk and low-risk groups was successfully built.</p><h3 class="Heading">Results</h3><p class="Para">Using a combined strategy, we initially identified 2472 significant survival-related genes. Functional enrichment analysis demonstrated these genes' relevance to tumor initiation and progression. Using the LASSO method, we successfully built a reliable risk prediction model. The risk model was validated in two external sets and an independent set. The expression of these 16 genes was highly correlated with patients' risk. High-risk group patients witnessed poorer recurrence-free survival (RFS) and overall survival (OS) compared to low-risk group patients. Moreover, stratification analysis and decision curve analysis (DCA) confirmed the independence and potential translational value of this predictive tool. We also built a nomogram comprising risk model and stage to predict OS for LUAD patients.</p><h3 class="Heading">Conclusions</h3><p class="Para">Our risk model may serve as a practical and reliable prognosis predictive tool for LUAD and could provide novel insights into the understanding of the molecular mechanism of this disease.</p>

oncology
Identification of Genes Associated with Lung Adenocarcinoma Prognosis

Zhe-Hao He,Wang Lv,Lu-Ming Wang,Yi-Qing Wang,Jian Hu

DOI: https://doi.org/10.2174/1386207322666190404152140

2019-01-01

Combinatorial Chemistry & High Throughput Screening

Abstract:Objective: Lung cancer is the most prevalent cancer in the world, and lung adenocarcinoma is the most common lung cancer subtype. Identification and determination of relevant prognostic markers are the key steps to personalized cancer management. Methods: We collected the gene expression profiles from 265 tumor tissues of stage I patients from The Cancer Genome Atlas (TCGA) databases. Using Cox regression model, we evaluated the association between gene expression and the overall survival time of patients adjusting for gender and age at initial pathologic diagnosis. Results: Age at initial pathologic diagnosis was identified to be associated with the survival, while gender was not. We identified that 15 genes were significantly associated with overall survival time of patients (FDR < 0.1). The 15-mRNA signature- based risk score was helpful to distinguish patients of high-risk group from patients of low-risk group. Conclusion: Our findings reveal novel genes associated with lung adenocarcinoma survival and extend our understanding of how gene expression contributes to lung adenocarcinoma survival. These results are helpful for the prediction of the prognosis and personalized cancer management.
Additional File 2 of IRGS: an Immune-Related Gene Classifier for Lung Adenocarcinoma Prognosis

Xiaoshun Shi,Ruidong Li,Xiaoying Dong,Allen M. Chen,Xiguang Liu,Daru Lu,Siyang Feng,He Wang,Kaican Cai

DOI: https://doi.org/10.6084/m9.figshare.11805678

2020-01-01

Abstract:Additional file 2: Table S1. Differentially expressed genes in the TCGA-LUAD dataset.
Additional File 3 of Exploration of Predictive and Prognostic Alternative Splicing Signatures in Lung Adenocarcinoma Using Machine Learning Methods

Qidong Cai,Boxue He,Pengfei Zhang,Zhenyu Zhao,Ping Xiong,Yuqian Zhang,Haiyang Xie,Xiang Wang

DOI: https://doi.org/10.6084/m9.figshare.13346463

2020-01-01

Abstract:Additional file 3: Table S3. Samples for recognizing lymph node metastasis (LNM).
Identification of Key Genes in Lung Adenocarcinoma and Establishment of Prognostic Mode

Zhou Jiawei,Mu Min,Xing Yingru,Zhang Xin,Li Danting,Liu Yafeng,Xie Jun,Hu Wangfa,Zhang Lijun,Wu Jing,Hu Dong

DOI: https://doi.org/10.3389/fmolb.2020.561456

IF: 6.113

2020-10-27

Frontiers in Molecular Biosciences

Abstract:<span><b>Background:</b> The development of human tumors is associated with the abnormal expression of various functional genes, and a massive tumor-based database needs to be deeply mined. Based on a multigene prediction model, access to urgent prognosis of patients has become possible.<b>Materials and Methods:</b> We selected three RNA expression profiles (GSE32863, GSE10072, and GSE43458) from the lung adenocarcinoma (LUAD) database of the Gene Expression Omnibus (GEO) and analyzed the differentially expressed genes (DEGs) between tumor and normal tissue using GEO2R program. After that, we analyzed the transcriptome data of 479 LUAD samples (54 normal tissue samples and 425 cancer tissue samples) and their clinical follow-up data from the (TCGA) database. Kaplan–Meier (KM) curve and receiver operating characteristic (ROC) were used to assess the prediction model. Multivariate Cox analysis was used to identify independent predictors. TCGA pancreatic adenocarcinoma datasets were used to establish a nomogram model.<b>Results:</b> We found 98 significantly prognosis-related genes using KM and COX analysis, among which six genes were found to be the DEGs in GEO. Using multivariate analysis, it was found that a single gene could not be used as an independent predictor of prognosis. However, the risk score calculated by weighting these six genes could serve as an independent prognosis predictor. COX analysis performed with multiple covariates such as age, gender, tumor stage, and TNM typing showed that risk score could still be utilized as an independent risk factor for patient survival rate (<i>p</i> = 0.013) and had an applicable reliability (area under the curve, AUC = 0.665). By combining risk score and various clinical features, the nomogram model was constructed, which had been proven to have high consistency for the prediction of 3- and 5-year survival rate (concordance = 0.751) and high accuracy as tested by ROC (AUC = 0.71;AUC = 0.708).<b>Conclusion:</b> We proposed a method to predict the prognosis of LUAD by weighting multiple genes and constructed a nomogram model suitable for the prognostic evaluation of LUAD, which could provide a new tool for the identification of therapeutic targets and the efficacy evaluation of LUAD.</span>

biochemistry & molecular biology
Large-scale Gene Expression Analysis Reveals Robust Gene Signatures for Prognosis Prediction in Lung Adenocarcinoma

Yiyan Songyang,Wei Zhu,Cong Liu,Lin-lin Li,Wei Hu,Qun Zhou,Han Zhang,Wen Li,Dejia Li

DOI: https://doi.org/10.7717/peerj.6980

IF: 3.061

2019-01-01

PeerJ

Abstract:Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death worldwide. High mortality in LUAD motivates us to stratify the patients into high- and low-risk groups, which is beneficial for the clinicians to design a personalized therapeutic regimen. To robustly predict the risk, we identified a set of robust prognostic gene signatures and critical pathways based on ten gene expression datasets by the meta-analysis-based Cox regression model, 25 of which were selected as predictors of multivariable Cox regression model by MMPC algorithm. Gene set enrichment analysis (GSEA) identified the Aurora-A pathway, the Aurora-B pathway, and the FOXM1 transcription factor network as prognostic pathways in LUAD. Moreover, the three prognostic pathways were also the biological processes of G2-M transition, suggesting that hyperactive G2-M transition in cell cycle was an indicator of poor prognosis in LUAD. The validation in the independent datasets suggested that overall survival differences were observed not only in all LUAD patients, but also in those with a specific TNM stage, gender, and age group. The comprehensive analysis demonstrated that prognostic signatures and the prognostic model by the large-scale gene expression analysis were more robust than models built by single data based gene signatures in LUAD overall survival prediction.
5-Mrna-based Prognostic Signature of Survival in Lung Adenocarcinoma

Qian-Lin Xia,Xiao-Meng He,Yan Ma,Qiu-Yue Li,Yu-Zhen Du,Jin Wang

DOI: https://doi.org/10.5306/wjco.v14.i1.27

2023-01-01

World Journal of Clinical Oncology

Abstract:BACKGROUND Lung adenocarcinoma (LUAD) is the most common non-small-cell lung cancer, with a high incidence and a poor prognosis. AIM To construct effective predictive models to evaluate the prognosis of LUAD patients. METHODS In this study, we thoroughly mined LUAD genomic data from the Gene Expression Omnibus (GEO) (GSE43458, GSE32863, and GSE27262) and the Cancer Genome Atlas (TCGA) datasets, including 698 LUAD and 172 healthy (or adjacent normal) lung tissue samples. Univariate regression and LASSO regression analyses were used to screen differentially expressed genes (DEGs) related to patient prognosis, and multivariate Cox regression analysis was applied to establish the risk score equation and construct the survival prognosis model. Receiver operating characteristic curve and Kaplan-Meier survival analyses with clinically independent prognostic parameters were performed to verify the predictive power of the model and further establish a prognostic nomogram. RESULTS A total of 380 DEGs were identified in LUAD tissues through GEO and TCGA datasets, and 5 DEGs (TCN1, CENPF, MAOB, CRTAC1 and PLEK2) were screened out by multivariate Cox regression analysis, indicating that the prognostic risk model could be used as an independent prognostic factor (Hazard ratio = 1.520, P < 0.001). Internal and external validation of the model confirmed that the prediction model had good sensitivity and specificity (Area under the curve = 0.754, 0.737). Combining genetic models and clinical prognostic factors, nomograms can also predict overall survival more effectively. CONCLUSION A 5-mRNA-based model was constructed to predict the prognosis of lung adenocarcinoma, which may provide clinicians with reliable prognostic assessment tools and help clinical treatment decisions.
Histopathological Images and Multi-Omics Integration Predict Molecular Characteristics and Survival in Lung Adenocarcinoma

Linyan Chen,Hao Zeng,Yu Xiang,Yeqian Huang,Yuling Luo,Xuelei Ma

DOI: https://doi.org/10.3389/fcell.2021.720110

IF: 5.5

2021-10-11

Frontiers in Cell and Developmental Biology

Abstract:Histopathological images and omics profiles play important roles in prognosis of cancer patients. Here, we extracted quantitative features from histopathological images to predict molecular characteristics and prognosis, and integrated image features with mutations, transcriptomics, and proteomics data for prognosis prediction in lung adenocarcinoma (LUAD). Patients obtained from The Cancer Genome Atlas (TCGA) were divided into training set ( n = 235) and test set ( n = 235). We developed machine learning models in training set and estimated their predictive performance in test set. In test set, the machine learning models could predict genetic aberrations: ALK (AUC = 0.879), BRAF (AUC = 0.847), EGFR (AUC = 0.855), ROS1 (AUC = 0.848), and transcriptional subtypes: proximal-inflammatory (AUC = 0.897), proximal-proliferative (AUC = 0.861), and terminal respiratory unit (AUC = 0.894) from histopathological images. Moreover, we obtained tissue microarrays from 316 LUAD patients, including four external validation sets. The prognostic model using image features was predictive of overall survival in test and four validation sets, with 5-year AUCs from 0.717 to 0.825. High-risk and low-risk groups stratified by the model showed different survival in test set (HR = 4.94, p < 0.0001) and three validation sets (HR = 1.64–2.20, p < 0.05). The combination of image features and single omics had greater prognostic power in test set, such as histopathology + transcriptomics model (5-year AUC = 0.840; HR = 7.34, p < 0.0001). Finally, the model integrating image features with multi-omics achieved the best performance (5-year AUC = 0.908; HR = 19.98, p < 0.0001). Our results indicated that the machine learning models based on histopathological image features could predict genetic aberrations, transcriptional subtypes, and survival outcomes of LUAD patients. The integration of histopathological images and multi-omics may provide better survival prediction for LUAD.

cell biology,developmental biology
Additional File 3 of Construction of a Predictive Model for Immunotherapy Efficacy in Lung Squamous Cell Carcinoma Based on the Degree of Tumor-Infiltrating Immune Cells and Molecular Typing

Lingge Yang,Shuli Wei,Jingnan Zhang,Qiongjie Hu,Wansong Hu,Mengqing Cao,Long Zhang,Yongfang Wang,Pingli Wang,Kai Wang

DOI: https://doi.org/10.6084/m9.figshare.20484975

2022-01-01

Abstract:Additional file 3: Table S2. The main clinical information of TCGA-LUSC, GSE126044, GSE135222 and our independent LUSC cohort.
Identification and Validation of Two Lung Adenocarcinoma-Development Characteristic Gene Sets for Diagnosing Lung Adenocarcinoma and Predicting Prognosis

Cheng Liu,Xiang Li,Hua Shao,Dan Li

DOI: https://doi.org/10.3389/fgene.2020.565206

IF: 3.7

2020-12-21

Frontiers in Genetics

Abstract:Background : Lung adenocarcinoma (LUAD) is one of the main types of lung cancer. Because of its low early diagnosis rate, poor late prognosis, and high mortality, it is of great significance to find biomarkers for diagnosis and prognosis. Methods : Five hundred and twelve LUADs from The Cancer Genome Atlas were used for differential expression analysis and short time-series expression miner (STEM) analysis to identify the LUAD-development characteristic genes. Survival analysis was used to identify the LUAD-unfavorable genes and LUAD-favorable genes. Gene set variation analysis (GSVA) was used to score individual samples against the two gene sets. Receiver operating characteristic (ROC) curve analysis and univariate and multivariate Cox regression analysis were used to explore the diagnostic and prognostic ability of the two GSVA score systems. Two independent data sets from Gene Expression Omnibus (GEO) were used for verifying the results. Functional enrichment analysis was used to explore the potential biological functions of LUAD-unfavorable genes. Results : With the development of LUAD, 185 differentially expressed genes (DEGs) were gradually upregulated, of which 84 genes were associated with LUAD survival and named as LUAD-unfavorable gene set. While 237 DEGs were gradually downregulated, of which 39 genes were associated with LUAD survival and named as LUAD-favorable gene set. ROC curve analysis and univariate/multivariate Cox proportional hazards analyses indicated both of LUAD-unfavorable GSVA score and LUAD-favorable GSVA score were a biomarker of LUAD. Moreover, both of these two GSVA score systems were an independent factor for LUAD prognosis. The LUAD-unfavorable genes were significantly involved in p53 signaling pathway, Oocyte meiosis, and Cell cycle. Conclusion : We identified and validated two LUAD-development characteristic gene sets that not only have diagnostic value but also prognostic value. It may provide new insight for further research on LUAD.

genetics & heredity
Additional File 8 of Exploration of Predictive and Prognostic Alternative Splicing Signatures in Lung Adenocarcinoma Using Machine Learning Methods

Qidong Cai,Boxue He,Pengfei Zhang,Zhenyu Zhao,Ping Xiong,Yuqian Zhang,Haiyang Xie,Xiang Wang

DOI: https://doi.org/10.6084/m9.figshare.13346478

2020-01-01

Abstract:Additional file 8: Table S8. Survival-related alternative splicing events selected by random survival forest model.
Machine learning-based integration of CD8 T cell-related gene signatures for comprehensive prognostic assessment in lung adenocarcinoma

Jing Yong,Dongdong Wang,Huiming Yu

DOI: https://doi.org/10.21037/tcr-23-2332

2024-07-31

Abstract:Background: Lung adenocarcinoma (LUAD) stands as the most prevalent histological subtype of lung cancer, exhibiting heterogeneity in outcomes and diverse responses to therapy. CD8 T cells are consistently present throughout all stages of tumor development and play a pivotal role within the tumor microenvironment (TME). Our objective was to investigate the expression profiles of CD8 T cell marker genes, establish a prognostic risk model based on these genes in LUAD, and explore its relationship with immunotherapy response. Methods: By leveraging the expression data and clinical records from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts, we identified 23 consensus prognostic genes. Employing ten machine-learning algorithms, we generated 101 combinations, ultimately selecting the optimal algorithm to construct an artificial intelligence-derived prognostic signature named riskScore. This selection was based on the average concordance index (C-index) across three testing cohorts. Results: RiskScore emerged as an independent risk factor for overall survival (OS), progression-free interval (PFI), disease-free interval (DFI), and disease-specific survival (DSS) in LUAD. Notably, riskScore exhibited notably superior predictive accuracy compared to traditional clinical variables. Furthermore, we observed a positive correlation between the high-risk riskScore group and tumor-promoting biological functions, lower tumor mutational burden (TMB), lower neoantigen (NEO) load, and lower microsatellite instability (MSI) scores, as well as reduced immune cell infiltration and an increased probability of immune evasion within the TME. Of significance, the immunophenoscore (IPS) score displayed significant differences among risk subgroups, and riskScore effectively stratified patients in the IMvigor210 and GSE135222 immunotherapy cohort based on their survival outcomes. Additionally, we identified potential drugs that could target specific risk subgroups. Conclusions: In summary, riskScore demonstrates its potential as a robust and promising tool for guiding clinical management and tailoring individualized treatments for LUAD patients.
Machine Learning-Based Immune Prognostic Model and Cerna Network Construction for Lung Adenocarcinoma

Xiaoqian He,Ying Su,Pei Liu,Cheng Chen,Chen,Haoqin Guan,Xiaoyi Lv,Wenjia Guo

DOI: https://doi.org/10.1007/s00432-023-04609-1

2023-01-01

Journal of Cancer Research and Clinical Oncology

Abstract:PURPOSE:Lung adenocarcinoma (LUAD) is a malignant tumor with a high lethality rate. Immunotherapy has become a breakthrough in cancer treatment and improves patient survival and prognosis. Therefore, it is necessary to find new immune-related markers. However, the current research on immune-related markers in LUAD is not sufficient. Therefore, there is a need to find new immune-related biomarkers to help treat LUAD patients. METHODS:In this study, a bioinformatics approach combined with a machine learning approach screened reliable immune-related markers to construct a prognostic model to predict the overall survival (OS) of LUAD patients, thus promoting the clinical application of immunotherapy in LUAD. The experimental data were obtained from The Cancer Genome Atlas (TCGA) database, including 535 LUAD and 59 healthy control samples. Firstly, the Hub gene was screened using a bioinformatics approach combined with the Support Vector Machine Recursive Feature Elimination algorithm; then, a multifactorial Cox regression analysis by constructing an immune prognostic model for LUAD and a nomogram to predict the OS rate of LUAD patients. Finally, the regulatory mechanism of Hub genes in LUAD was analyzed by ceRNA. RESULTS:Five genes, ADM2, CDH17, DKK1, PTX3, and AC145343.1, were screened as potential immune-related genes in LUAD. Among them, ADM2 and AC145343.1 had a good prognosis in LUAD patients (HR < 1) and were novel markers. The remaining three genes screened were associated with poor prognosis in LUAD patients (HR > 1). In addition, the experimental results showed that patients in the low-risk group had better OS rates than those in the high-risk group (P < 0.001). CONCLUSION:In this paper, we propose an immune prognostic model to predict OS rate in LUAD patients and show the correlation between five immune genes and the level of immune-related cell infiltration. It provides new markers and additional ideas for immunotherapy in patients with LUAD.
Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Data to Establish and Validate a Prognostic Model for Patients With Lung Adenocarcinoma

Aimin Jiang,Jingjing Wang,Na Liu,Xiaoqiang Zheng,Yimeng Li,Yuyan Ma,Haoran Zheng,Xue Chen,Chaoxin Fan,Rui Zhang,Xiao Fu,Yu Yao

DOI: https://doi.org/10.3389/fgene.2022.833797

IF: 3.7

2022-01-27

Frontiers in Genetics

Abstract:Background: Lung adenocarcinoma (LUAD) remains a lethal disease worldwide, with numerous studies exploring its potential prognostic markers using traditional RNA sequencing (RNA- seq ) data. However, it cannot detect the exact cellular and molecular changes in tumor cells. This study aimed to construct a prognostic model for LUAD using single-cell RNA- seq (scRNA- seq ) and traditional RNA- seq data. Methods: Bulk RNA- seq data were downloaded from The Cancer Genome Atlas (TCGA) database. LUAD scRNA- seq data were acquired from Gene Expression Omnibus (GEO) database. The uniform manifold approximation and projection (UMAP) was used for dimensionality reduction and cluster identification. Weighted Gene Correlation Network Analysis (WGCNA) was utilized to identify key modules and differentially expressed genes (DEGs). The non-negative Matrix Factorization (NMF) algorithm was used to identify different subtypes based on DEGs. The Cox regression analysis was used to develop the prognostic model. The characteristics of mutation landscape, immune status, and immune checkpoint inhibitors (ICIs) related genes between different risk groups were also investigated. Results: scRNA- seq data of four samples were integrated to identify 13 clusters and 9cell types. After applying differential analysis, NK cells, bladder epithelial cells, and bronchial epithelial cells were identified as significant cell types. Overall, 329 DEGs were selected for prognostic model construction through differential analysis and WGCNA. Besides, NMF identified two clusters based on DEGs in the TCGA cohort, with distinct prognosis and immune characteristics being observed. We developed a prognostic model based on the expression levels of six DEGs. A higher risk score was significantly correlated with poor survival outcomes but was associated with a more frequent TP53 mutation rate, higher tumor mutation burden (TMB), and up-regulation of PD-L1 . Two independent external validation cohorts were also adopted to verify our results, with consistent results observed in them. Conclusion: This study constructed and validated a prognostic model for LUAD by integrating 10× scRNA- seq and bulk RNA- seq data. Besides, we observed two distinct subtypes in this population, with different prognosis and immune characteristics.

genetics & heredity
Integrated machine learning to predict the prognosis of lung adenocarcinoma patients based on SARS‐COV‐2 and lung adenocarcinoma crosstalk genes

Yanan Wu,Yishuang Cui,Xuan Zheng,Xuemin Yao,Guogui Sun

DOI: https://doi.org/10.1111/cas.16384

IF: 5.7

2024-11-05

Cancer Science

Abstract:The primary goal of this research is to elucidate the interplay of genes between SARS‐CoV‐2 infection and lung adenocarcinoma, with a preliminary investigation into their clinical significance and underlying molecular mechanisms. Viruses are widely recognized to be intricately associated with both solid and hematological malignancies in humans. The primary goal of this research is to elucidate the interplay of genes between SARS‐CoV‐2 infection and lung adenocarcinoma (LUAD), with a preliminary investigation into their clinical significance and underlying molecular mechanisms. Transcriptome data for SARS‐CoV‐2 infection and LUAD were sourced from public databases. Differentially expressed genes (DEGs) associated with SARS‐CoV‐2 infection were identified and subsequently overlapped with TCGA‐LUAD DEGs to discern the crosstalk genes (CGs). In addition, CGs pertaining to both diseases were further refined using LUAD TCGA and GEO datasets. Univariate Cox regression was conducted to identify genes associated with LUAD prognosis, and these genes were subsequently incorporated into the construction of a prognosis signature using 10 different machine learning algorithms. Additional investigations, including tumor mutation burden assessment, TME landscape, immunotherapy response assessment, as well as analysis of sensitivity to antitumor drugs, were also undertaken. We discovered the risk stratification based on the prognostic signature revealed that the low‐risk group demonstrated superior clinical outcomes (p

oncology
Genome-Wide Analysis of Lung Adenocarcinoma Identifies Novel Prognostic Factors and a Prognostic Score.

Donglai Chen,Yueqiang Song,Fuquan Zhang,Xiaofan Wang,Erjia Zhu,Xi Zhang,Gening Jiang,Siguang Li,Chang Chen,Yongbing Chen

DOI: https://doi.org/10.3389/fgene.2019.00493

IF: 3.7

2019-01-01

Frontiers in Genetics

Abstract:BACKGROUND AND OBJECTIVE:Lung adenocarcinoma (LUAD) is the most common histological type of all lung cancers and is associated with genetic and epigenetic aberrations. The tumor, node, and metastasis (TNM) stage is the most authoritative indicator of the clinical outcome in LUAD patients in current clinical practice. In this study, we attempted to identify novel genetic and epigenetic modifications and integrate them as a predictor of the prognosis for LUAD, to supplement the TNM stage with additional information.METHODS:A dataset of 445 patients with LUAD was obtained from The Cancer Genome Atlas database. Both genetic and epigenetic aberrations were screened for their prognostic impact on overall survival (OS). A prognostic score (PS) integrating all the candidate prognostic factors was then developed and its prognostic value validated.RESULTS:A total of two micro-RNAs, two mRNAs and two DNA methylation sites were identified as prognostic factors associated with OS. The low- and high-risk patient groups, divided by their PS level, showed significantly different OS (p < 0.001) and recurrence-free survival (RFS; p = 0.005). Patients in the early stages (stages I/II) and advanced stages (stages III/IV) of LUAD could be further subdivided by PS into four subgroups. PS remained efficient in stratifying patients into different OS (p < 0.001) and RFS (p = 0.005) when the low- and high-risk subgroups were in the early stages of the disease. However, there was only a significant difference in OS (p = 0.04) but not RFS (p = 0.2), between the low-risk and high-risk subgroups when both were in advanced stages.CONCLUSION:PS, in combination with the TNM stage, provides additional precision in stratifying patients with significantly different OS and RFS prognoses. Further studies are warranted to assess the efficiency of PS and to explain the effects of the genetic and epigenetic aberrations observed in LUAD.
Development And Validation Of A Seven-Gene Signature For Predicting The Prognosis Of Lung Adenocarcinoma

Yingqing Zhang,Xiaoping Zhang,Xiaodong Lv,Ming Zhang,Xixi Gao,Jialiang Liu,Yufen Xu,Zhixian Fang,Wenyu Chen

DOI: https://doi.org/10.1155/2020/1836542

2020-01-01

BioMed Research International

Abstract:Background. Prognosis is a main factor affecting the survival of patients with lung adenocarcinoma (LUAD), yet no robust prognostic model of high effectiveness has been developed. This study is aimed at constructing a stable and practicable gene signature-based model via bioinformatics methods for predicting the prognosis of LUAD sufferers. Methods. The mRNA expression data were accessed from the TCGA-LUAD dataset, and paired clinical information was collected from the GDC website. R package "edgeR" was employed to select the differentially expressed genes (DEGs), which were then used for the construction of a gene signaturebased model via univariate COX, Lasso, and multivariate COX regression analyses. Kaplan-Meier and ROC survival analyses were conducted to comprehensively evaluate the performance of the model in predicting LUAD prognosis, and an independent dataset GSE26939 was accessed for further validation. Results. Totally, 1,655 DEGs were obtained, and a 7-gene signature-based risk score was developed and formulated as risk score = 0:000245 * NTSR1 + o7:13E - 05THORN * RHOV + 0:000505 * KLK8 + o7:01E - 05THORN * TNS4 + 0:000288 * C1QTNF6 + 0:00044 * IVL + 0:000161 * B4GALNT2. Kaplan-Meier survival curves revealed that the survival rate of patients in the high-risk group was lower in both the TCGA-LUAD dataset and GSE26939 relative to that of patients in the low-risk group. The relationship between the risk score and clinical characteristics was further investigated, finding that the model was effective in prognosis prediction in the patients with different age (age > 65, age < 65) and TNM stage (N0&N1, T1&T2, and tumor stage I/II). In sum, our study provides a robust predictive model for LUAD prognosis, which boosts the clinical research on LUAD and helps to explore the mechanism underlying the occurrence and progression of LUAD.

Additional File 2: of A Large Cohort Study Identifying a Novel Prognosis Prediction Model for Lung Adenocarcinoma Through Machine Learning Strategies

Additional File 6: of A Large Cohort Study Identifying a Novel Prognosis Prediction Model for Lung Adenocarcinoma Through Machine Learning Strategies

Additional File 1 of Integration of Single-Cell Regulon Atlas and Multi-Omics Data for Prognostic Stratification and Personalized Treatment Prediction in Human Lung Adenocarcinoma

LUADpp: an Effective Prediction Model on Prognosis of Lung Adenocarcinomas Based on Somatic Mutational Features

A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies

Identification of Genes Associated with Lung Adenocarcinoma Prognosis

Additional File 2 of IRGS: an Immune-Related Gene Classifier for Lung Adenocarcinoma Prognosis

Additional File 3 of Exploration of Predictive and Prognostic Alternative Splicing Signatures in Lung Adenocarcinoma Using Machine Learning Methods

Identification of Key Genes in Lung Adenocarcinoma and Establishment of Prognostic Mode

Large-scale Gene Expression Analysis Reveals Robust Gene Signatures for Prognosis Prediction in Lung Adenocarcinoma

5-Mrna-based Prognostic Signature of Survival in Lung Adenocarcinoma

Histopathological Images and Multi-Omics Integration Predict Molecular Characteristics and Survival in Lung Adenocarcinoma

Additional File 3 of Construction of a Predictive Model for Immunotherapy Efficacy in Lung Squamous Cell Carcinoma Based on the Degree of Tumor-Infiltrating Immune Cells and Molecular Typing

Identification and Validation of Two Lung Adenocarcinoma-Development Characteristic Gene Sets for Diagnosing Lung Adenocarcinoma and Predicting Prognosis

Additional File 8 of Exploration of Predictive and Prognostic Alternative Splicing Signatures in Lung Adenocarcinoma Using Machine Learning Methods

Machine learning-based integration of CD8 T cell-related gene signatures for comprehensive prognostic assessment in lung adenocarcinoma

Machine Learning-Based Immune Prognostic Model and Cerna Network Construction for Lung Adenocarcinoma

Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Data to Establish and Validate a Prognostic Model for Patients With Lung Adenocarcinoma

Integrated machine learning to predict the prognosis of lung adenocarcinoma patients based on SARS‐COV‐2 and lung adenocarcinoma crosstalk genes

Genome-Wide Analysis of Lung Adenocarcinoma Identifies Novel Prognostic Factors and a Prognostic Score.

Development And Validation Of A Seven-Gene Signature For Predicting The Prognosis Of Lung Adenocarcinoma